Abstract Number: 1639 • 2015 ACR/ARHP Annual Meeting
Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
Background/Purpose: Treatment options delivering sustained efficacy when given as monotherapy in RA are limited.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of…Abstract Number: 2680 • 2015 ACR/ARHP Annual Meeting
Severity of Morning Stiffness Is Associated More Strongly with Disease Activity in Patients with Rheumatoid Arthritis
Morning stiffness (MS) is a complex symptom involving pain and functional limitation. It is not included in the ACR/EULAR 2010 classification criteria for rheumatoid arthritis…Abstract Number: 49 • 2015 ACR/ARHP Annual Meeting
Dose Relationship Between Oral Glucocorticoids and TNF Inhibitors and the Risk of Hospitalized Infectious Events Among Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for serious hospitalized infectious events (HIEs). Research suggests that tumor necrosis factor alpha inhibitors…Abstract Number: 995 • 2015 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Only a Few Expanded T-Cell Clones Dominate in Joint Inflammation: A Study in Seven RA Patients Undergoing Paired Synovial Tissue Biopsies in Multiple Joints
Background/Purpose: Previously we found a strong enrichment of highly expanded T-cell clones in rheumatoid arthritis (RA) synovial tissue of inflamed joints. To gain more insight…Abstract Number: 1640 • 2015 ACR/ARHP Annual Meeting
Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). ORAL Scan was a 2-year, randomized, Phase 3, clinical trial…Abstract Number: 2696 • 2015 ACR/ARHP Annual Meeting
Geography and Association Between Patient Reported Outcomes and Disease Activity (DAS28) Components in Patients with Rheumatoid Arthritis, Among 17 Countries
Background/Purpose: 28 joints-disease activity score (DAS28) is routinely used in clinical practice to assess disease activity in rheumatoid arthritis (RA). DAS28, particularly its subjective components…Abstract Number: 123 • 2015 ACR/ARHP Annual Meeting
An Economic Evaluation of Tofacitinib (Xeljanz) Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the US
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). An economic model was developed to evaluate the treatment…Abstract Number: 1112 • 2015 ACR/ARHP Annual Meeting
Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Background/Purpose: Obinutuzumab (OBZ, a Type II anti-CD20 monoclonal antibody [mAb] with afucosylated Fc portion and enhanced affinity for Fcγ receptor III) is more efficient than…Abstract Number: 1645 • 2015 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…Abstract Number: 2720 • 2015 ACR/ARHP Annual Meeting
Crucial Role of Nuclear Factor of Activated T Cell 5 (NFAT5), an Osmo-Protective Factor, in Migration and Invasion of Rheumatoid Synoviocytes
Background/Purpose: Fibroblast-like synoviocytes (FLS) play an important role in the progression of rheumatoid arthritis (RA). Particularly, FLS of RA patients (RA-FLS) exhibit pro-migratory and invasive…Abstract Number: 128 • 2015 ACR/ARHP Annual Meeting
Economic Burden and Treatment Patterns of Cycling Between Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) Among Patients with Rheumatoid Arthritis (RA)
Background/Purpose: RA patients with inadequate treatment response often cycle non-biologic DMARDs before initiating a biologic DMARD. Early and aggressive treatment is a key feature of…Abstract Number: 1169 • 2015 ACR/ARHP Annual Meeting
Crossregulatory Mechanisms Between Synovial Fibroblasts and Macrophages Relevant in RA Pathogenesis
Background/Purpose: Macrophages and synovial fibroblasts function as key drivers of inflammation in rheumatoid arthritis (RA). We have developed a co-culture system that aims to define…Abstract Number: 1655 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan
Background/Purpose: Monotherapy accounts for approximately 30% of biologic disease-modifying anti-rheumatic drug (DMARD) use in RA (Emery P et al. Ann Rheum Dis 2013;72:1897-904). A validated…Abstract Number: 2742 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc pooled analysis was designed to assess the efficacy and safety…Abstract Number: 152 • 2015 ACR/ARHP Annual Meeting
Anti-CCP Positive Patients without Clinical Synovitis Progress If Ultrasound Positive
Background/Purpose: To determine whether ultrasound can identify which anti-cyclic citrullinated peptide (anti-CCP) antibody positive patients with musculoskeletal (MSK) symptoms and without clinical synovitis progress to…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 56
- Next Page »